Drug
Ivonescimab clinical trials
Also written AK112 and SMT112.
- studies test it
- 132
- open now
- 111
- in phase 3
- 15
- first study started
- 2010
Keep track of what changes. Save the ivonescimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
129 studies that test it; most in 2025 (56); 3 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 20 |
| 2025 | 56 |
| 2026 | 35 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 30
- Phase 2
- 106
- Phase 3
- 15
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 43 · Other 89
Akeso (32) · M.D. Anderson Cancer Center (9) · Sun Yat-sen University (8) · Summit Therapeutics (5) · Fudan University (5) · Memorial Sloan Kettering Cancer Center (5) · Peking University Cancer Hospital & Institute (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3)
Often tested with
Tested in the same studies.
Cadonilimab (8) · Paclitaxel (6) · Docetaxel (6) · Albumin-Bound Paclitaxel (4) · Gemcitabine (4) · Carboplatin (4) · Ligufalimab (3) · Trastuzumab rezetecan (3)
Studies
Open first, then newest update. How each study uses ivonescimab is read from its arms, and is right about nine times in ten.
Testing it · 132
- Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)RecruitingPhase 2Guangdong Provincial People's HospitalNCT07472478Written as Ivonescimab Combined With Chemotherapy
- Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell CancerRecruitingPhase 2City of Hope Medical CenterNCT07226544Written as Ivonescimab
- A Study of Ivonescimab in People With LeiomyosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07516925Written as Ivonescimab
- Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural MesotheliomaNot yet recruitingPhase 1/2Ruijin HospitalNCT07885319Written as Ivonescimab Combined With Chemotherapy
- A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland CancersRecruitingPhase 2Dana-Farber Cancer InstituteNCT06805617Written as Ivonescimab
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerNot yet recruitingPhase 2Summit TherapeuticsNCT07877194Written as Ivonescimab
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT07393555Written as Ivonescimab
- Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerRecruitingPhase 3Summit TherapeuticsNCT07228832Written as Drug: Ivonescimab Injection
- Ivonescimab for the Treatment of Thymic CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT06980077Written as Ivonescimab
- A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract CancerRecruitingPhase 2Haitao Zhao, MDNCT07854600Written as Ivonescimab
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)RecruitingPhase 1/2GlaxoSmithKlineNCT07602855Written as Ivonescimab
- A Study of Ivonescimab in People With Endometrial and Cervical CancersRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06925724Written as Ivonescimab
- STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)Not yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07743138Written as Ivonescimab
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1RecruitingPhase 3Summit TherapeuticsNCT06767514Written as Ivonescimab Injection
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07619339Written as Ivonescimab
- Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLCNot yet recruitingPhase 2Shaodong HongNCT07819591Written as Ivonescimab
- Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC PatientsNot yet recruitingPhase 1Everest Medicines (Beijing) Co., Ltd.NCT07614646Written as Ivonescimab
- Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsRecruitingPhase 2UNICANCERNCT06529718Written as Ivonescimab
- Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEARecruitingPhase 2Massachusetts General HospitalNCT07070466Written as Ivonescimab
- Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung CancerRecruitingPhase 2PrECOG, LLC.NCT07057791Written as Ivonescimab 10 mg/kg
See all 132 studies that test ivonescimab →
Given in every arm · 24 — ivonescimab is usual care beside what is tested
- Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal CancerNot yet recruitingPhase 1City of Hope Medical CenterNCT07363408Written as Ivonescimab
- Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBCNot yet recruitingPhase 2University of Kansas Medical CenterNCT07743632Written as Ivonescimab
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338Written as Ivonescimab
- AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07712094Written as AK112
- Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLCRecruitingPhase 2Massachusetts General HospitalNCT07405190Written as Ivonescimab
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07535437Written as Ivonescimab
- Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain MetsNot yet recruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT07234877Written as Ivonescimab
- Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.Not yet recruitingPhase 2Shanghai Allink Biotherapeutics Co., Ltd.NCT07603791Written as Ivonescimab Injection
- Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal AdenocarcinomaRecruitingPhase 2UNICANCERNCT06846346Written as Ivonescimab
- Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCRecruitingPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06868732Written as Ivonescimab
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract CancerRecruitingPhase 1/2AkesoNCT06938321Written as AK112
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic CancerRecruitingPhase 2AkesoNCT07114315Written as AK112
- First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant TumorsRecruitingPhase 1/2Shanghai JMT-Bio Inc.NCT06877650Written as Ivonescimab
- A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver MetastasesNot yet recruitingPhase 1/2AkesoNCT07357220Written as AK112
- Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical CancerNot yet recruitingPhase 2Women's Hospital School Of Medicine Zhejiang UniversityNCT07244965Written as Ivonescimab Combined With Chemotherapy
- A Study of Ivonescimab in First-Line ES-SCLCRecruitingPhase 2AkesoNCT07245446Written as Ivonescimab
- Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal MetastasisRecruitingPhase 1/2Guangzhou Medical UniversityNCT06809517Written as AK112
- Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT06957561Written as Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCActive, not recruitingPhase 2AkesoNCT05247684Written as AK112
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsActive, not recruitingPhase 1/2AkesoNCT05229497Written as AK112
Showing 20 of 24.
As the comparator · 1 — what is tested is compared with ivonescimab
Codes
What other systems call ivonescimab · ClinicalTrials.gg INT018524
- UNII (FDA) Y0O332CU66IVONESCIMABOne source FDA
- NCI Thesaurus C184865IvonescimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y0O332CU66 | IVONESCIMAB | One source FDA |
| NCI Thesaurus | C184865 | Ivonescimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.